The Centers for Medicare & Medicaid Services (CMS) issued an update Tuesday noting that a decision on a proposed National Coverage Determination (NCD) on transcatheter mitral valve repair (TMVR) is “forthcoming.”
The decision was due Friday, but that day came and went without a decision or any other updates.
The existing NCD, issued in 2014, covers TMVR for the treatment of significant symptomatic degenerative mitral regurgitation (MR). The Food and Drug Administration (FDA) extended the indication for MitraClip (Abbott) from treatment for degenerative MR to treatment for functional MR in March.
The CMS National Coverage Analysis (NCA) tracking sheet for TMVR indicates that the NCA is expected to be complete by May 14.